Vifor Pharma

Vifor Pharma P/S

Delisted·Dec 22, 2022

The (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Vifor Pharma (VIFN.SW) as of Nov 22, 2026 is 5.88. In the previous year, (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. was 6.29 — a change of -6.52% (lower).

P/S

5.88

YoY

-6.52%

Last updated:

As of Nov 22, 2026, Vifor Pharma's P/S ratio stood at 5.88, a -6.52% change from the 6.29 P/S ratio recorded in the previous year.

The Vifor Pharma P/S history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/S
Date
P/S
Jan 1, 2016
2.60 CHF
Jan 1, 2017
7.99 CHF
Jan 1, 2018
6.77 CHF
Jan 1, 2019
5.71 CHF
Jan 1, 2020
6.29 CHF
Jan 1, 2021
5.88 CHF
Jan 1, 2022 (e)
5.22 CHF
Jan 1, 2026 (e)
3.24 CHF
The Vifor Pharma P/S history
YEARP/SYoY
est3.24-37.93%
est5.22-11.18%
5.88-6.52%
6.29+10.07%
5.71-15.59%
6.77-15.31%
7.99+206.86%
2.60-7.93%
2.83-9.90%
3.14+81.45%
1.73+64.76%
1.05-6.25%
1.12-5.08%
1.18+59.46%
0.74+4.23%
0.71-44.09%
1.27+23.30%
1.03+41.10%
0.73+8.96%
0.67+55.81%
0.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Vifor Pharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Vifor Pharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Vifor Pharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Vifor Pharma grows earnings faster than its peers.

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

P/S Details

Decoding Vifor Pharma's P/S Ratio

Vifor Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Vifor Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Vifor Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Vifor Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Vifor Pharma stock

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Vifor Pharma is 5.88 in 2021.

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Vifor Pharma changed from 6.29 to 5.88, representing a -6.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Sales Ratio (P/S Ratio) is a financial metric that represents the ratio between the current price of a stock and the sales per share of the company. It is commonly used to assess the valuation of a stock compared to other stocks in the same industry or compared to the overall average of the stock market.

P/S Formula:
P/S = Price of a stock / Sales of a stock
If you can't find the Sales per Share (SPS) right away, which is the equivalent term for Revenue per Share in English, you can also calculate this value by dividing the company's total sales by the number of issued shares.

SPS Formula:
Total sales of the company / Number of issued shares
The Sales per Share or Revenue per Share can usually be easily found on most financial websites.

The P/S ratio is often used to assess the valuation of a stock compared to other stocks in the same industry or the overall stock market average. It can provide insights into how well the company is performing in terms of revenue per share compared to its competitors. A low P/S ratio may indicate that the company is generating relatively high revenue per share compared to other companies in the industry, which can be positive. On the other hand, a high P/S ratio may indicate that the company is generating relatively low revenue per share compared to its competitors, which can be negative.

To evaluate (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company.'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company..

A 'good' varies by industry and company stage. On Eulerpool, you can compare (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company.'s Vifor Pharma with sector peers and the industry average to assess whether it is attractive.

The P/S ratio when valuing a stock.

The price-to-sales ratio (P/S ratio) is an important tool of technical analysis that assists investors in evaluating stocks. It refers to the earnings per share of a company and its price movements. This indicator can be used to determine a stock's fair value, relative to the company's earnings.

History of the Price-to-Sales Ratio

The price-to-sales ratio is a relatively new indicator. It was first used in the 1980s by John Price when he developed the Price-to-Sales Index (PSI). Price wanted to find a way to value stocks taking into account their earnings. He noticed that many stock prices were not in line with their earnings situation. The PSI has since become an important analytical tool and is often referred to as the P/S ratio.

Calculation of the price-to-sales ratio

The price-to-sales ratio is easy to calculate. It is determined by dividing the current stock price by the company's earnings per share. P/S ratio = Stock price / Earnings per share. For example, if a company's stock price is $10 and the earnings per share is $2, then the P/S ratio is 5.

Application of the Price-to-Sales Ratio

The Price-to-Sales ratio is a useful tool for determining a fairly valued stock price. A low P/S ratio may indicate that a stock price is undervalued, which could be a good entry opportunity. However, a high Price-to-Sales ratio may indicate that a stock price is overvalued and investors should exercise caution.

An example: A company has a stock price of 20 USD and an earnings per share of 2 USD. The P/E ratio is 10. This could indicate that the stock price is overvalued and investors should be cautious before buying.

Investors and the price-to-sales ratio

Investors use the price-to-sales ratio to determine whether a company's stock price is fairly valued or not. They can compare the P/S ratio to see how the stock price relates to the company's earnings. Investors can also observe the P/S ratio over a longer period of time to see if the stock price changes in relation to the company's earnings.

Advantages and Disadvantages of the Price-to-Sales Ratio

The greatest advantage of the price-to-sales ratio is that it is a simple and understandable tool to determine the fair value of a stock price. It can also help investors identify stocks that are undervalued. One disadvantage is that the P/S ratio does not provide information about the company's profits. Therefore, investors should also consider other financial ratios before investing.

In today's time, the price-to-sales ratio is an important tool for investors to evaluate stocks and identify potential investment opportunities. It can help find a fairly valued stock price and identify stocks that are undervalued. However, investors should also consider other financial indicators before making an investment decision.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vifor Pharma

All Key Metrics — Vifor Pharma